New case of SCENESSE efficacy in vitiligo presented at AAD
Filed with ASX · · 5 pages · English
Watch Clinuvel Pharmaceuticals' latest callClinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call · Replay · Aug 27Read the transcript of Clinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings CallClinuvel Pharmaceuticals Limited on 6ix
Story so far
Earlier from Clinuvel Pharmaceuticals
- SCENESSE provides photoprotection in variegate porphyria
- CUV Appendix 4D Half Year Report
- Appendix 4E and Annual Report to Shareholders 2023
- Quarterly Activities/Appendix 4C Cash Flow Report
- Quarterly Activities/Appendix 4C Cash Flow Report Re-issued
Later from Clinuvel Pharmaceuticals
- CLINUVEL initiates on market share buy-back program
- afamelanotide in fair-skinned Parkinsons patients
- CLINUVEL extends Managing Director Employment Agreement
- Afamelanotide Assists DNA Repair Response Following UVR
- Vitiligo and Operational Update
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals